# A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)

> **NCT07190833** · PHASE1 · RECRUITING · sponsor: **Bionoxx Inc.** · enrollment: 27 (estimated)

## Conditions studied

- Treatment-Refractory Solid Tumors

## Interventions

- **DRUG:** OTS-412
- **DRUG:** Hydroxyurea (HU)
- **DRUG:** Hydroxyurea (HU)
- **DRUG:** Hydroxyurea (HU)
- **DRUG:** Hydroxyurea (HU)
- **DRUG:** Atezolizumab
- **DRUG:** OTS-412
- **DRUG:** OTS-412

## Key facts

- **NCT ID:** NCT07190833
- **Lead sponsor:** Bionoxx Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-09
- **Primary completion:** 2028-12
- **Final completion:** 2030-12
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07190833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07190833, "A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07190833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*